{"protocolSection":{"identificationModule":{"nctId":"NCT00322621","orgStudyIdInfo":{"id":"10258"},"secondaryIdInfos":[{"id":"F1J-MC-HMEM","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)","officialTitle":"Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain"},"statusModule":{"statusVerifiedDate":"2011-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-04"},"primaryCompletionDateStruct":{"date":"2007-10","type":"ACTUAL"},"completionDateStruct":{"date":"2007-10","type":"ACTUAL"},"studyFirstSubmitDate":"2006-05-05","studyFirstSubmitQcDate":"2006-05-05","studyFirstPostDateStruct":{"date":"2006-05-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2008-10-30","resultsFirstSubmitQcDate":"2009-11-13","resultsFirstPostDateStruct":{"date":"2009-12-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-02-03","lastUpdatePostDateStruct":{"date":"2011-02-07","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"},"collaborators":[{"name":"Boehringer Ingelheim","class":"INDUSTRY"}]},"descriptionModule":{"briefSummary":"To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy."},"conditionsModule":{"conditions":["Diabetic Neuropathies"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":216,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Duloxetine","type":"EXPERIMENTAL","description":"All subjects receive 30 mg once daily (QD), by mouth (per os - PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months. Patients beginning maintenance at the 60 mg QD dose could be increased to the 120 mg QD level if they did not maintain appropriate level of response throughout the maintenance period.","interventionNames":["Drug: Duloxetine"]}],"interventions":[{"type":"DRUG","name":"Duloxetine","armGroupLabels":["Duloxetine"],"otherNames":["LY248686","Cymbalta"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline (Week 8) in Brief Pain Inventory (BPI) 24-hour Average Pain Item Score at Week 34 Endpoint","description":"Maintenance effect of duloxetine 60 mg in patients with diabetic peripheral neuropathic pain (DPNP) was assessed by the change in BPI 24-hour average pain item score from baseline of the maintenance therapy arm (week 8) to 34 week endpoint in patients who achieved at least a 30 percent reduction on the BPI 24-hour average pain item after 8 weeks of acute therapy (Acute Therapy Phase). BPI is a self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 8), Week 34"}],"secondaryOutcomes":[{"measure":"Maintenance Arm: Number of Patients With a ≥50% Reduction From Baseline (Week 0) in Brief Pain Inventory 24-hour Average Pain Item","description":"A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 0), Week 34"},{"measure":"Rescue Arm: Number of Patients With a ≥50% Reduction From Baseline (Week 0) in Brief Pain Inventory 24-hour Average Pain Item","description":"A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 0), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Worst Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the worst pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Worst Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the worst pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Least Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the least pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Least Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the least pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Pain Score at 34 Week Endpoint","description":"A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Pain Right Now Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the pain right now. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Pain Right Now Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the pain right now. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: General Activity at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on general activity. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: General Activity at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on general activity. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Mood at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on mood. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Mood at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on mood. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Walking Ability at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on walking ability. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Walking Ability at 34 Week Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on walking ability. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Normal Work at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on normal work. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Normal Work at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on normal work. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Relations With Other People at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on relations with other people. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Relations With Other People at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on relations with other people. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Sleep at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on sleep. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Sleep at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on sleep. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Enjoyment of Life at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on enjoyment of life. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Enjoyment of Life at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on enjoyment of life. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Interference at Week 34 Endpoint","description":"A self-reported scale that measures interference of pain on average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Interference at Week 34 Endpoint","description":"A self-reported scale that measures interference of pain on average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average Interference scores range from 0 (does not interfere) to 10 (completely interferes).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Patient's Global Impressions of Improvement (PGI-I) at Week 34 Endpoint","description":"A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).","timeFrame":"Week 34"},{"measure":"Rescue Arm: Patient's Global Impressions of Improvement (PGI-I) at Week 34 Endpoint","description":"A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).","timeFrame":"Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Clinical Global Impressions of Severity (CGI-S) at Week 34 Endpoint","description":"Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Clinical Global Impressions of Severity (CGI-S) at Week 34 Endpoint","description":"Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Sensory Portion of the Short-Form McGill Pain Questionnaire at Week 34 Endpoint","description":"This instrument consists of 11 pain descriptors. The sensory pain portion scores range from 0 (none) to 3 (severe).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Sensory Portion of the Short-Form McGill Pain Questionnaire at Week 34 Endpoint","description":"This instrument consists of 11 pain descriptors. The sensory pain portion scores range from 0 (none) to 3 (severe).","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Maintenance Arm: Change From Baseline (Week 8) in Beck Depression Inventory-II (BDI-II) Total Score at Week 34 Endpoint","description":"A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Rescue Arm: Change From Baseline (Week 8) in Beck Depression Inventory-II (BDI-II) Total Score at Week 34 Endpoint","description":"A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.","timeFrame":"Baseline (Week 8), Week 34"},{"measure":"Number of Participants Discontinuing in the Acute Phase","timeFrame":"Baseline (Week 0) to Week 8"},{"measure":"Number of Participants Discontinuing in Maintenance / Rescue Phase","timeFrame":"Baseline (Week 8) to Week 34"},{"measure":"Change From Baseline in Vital Signs: Heart Rate at Week 34 Endpoint","timeFrame":"Baseline (Week 0), Week 34"},{"measure":"Change From Baseline (Week 0) in Vital Signs: Diastolic Blood Pressure at Week 34 Endpoint","timeFrame":"Baseline (Week 0), Week 34"},{"measure":"Change From Baseline (Week 0) in Vital Signs: Systolic Blood Pressure at Week 34 Endpoint","timeFrame":"Baseline (Week 0), Week 34"},{"measure":"Change From Baseline (Week 0) in Vital Signs: Weight at Week 34 Endpoint","timeFrame":"Baseline (Week 0), Week 34"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes with the pain beginning in the feet and present for at least 6 months.\n* May not be pregnant and agree to utilize medically acceptable and reliable means of birth control during participation in the study.\n* Score of 4 or greater on the Brief Pain Inventory on the 24-hour average pain item.\n\nExclusion Criteria:\n\n* History of substance abuse or dependence within the past year, excluding nicotine and caffeine.\n* Serious or unstable cardiovascular, hepatic (acute liver injury such as hepatitis or severe cirrhosis),kidney, respiratory, or blood disorder, seizure disorder, problems with peripheral vascular disease, or other medical conditions or psychiatric conditions that would hinder your participation or be likely to lead to hospitalization during the course of the study.\n* Taking monoamine oxidase inhibitor (MAOI) within 14 days of starting the study or the potential need to take during or within 5 days after discontinuation from the study.\n* Treatment with fluoxetine within 30 days of starting the study.\n* Unstable blood sugar control and uncontrolled or poorly controlled hypertension.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fortaleza","zip":"60120-020","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Porto Alegre","zip":"90035170","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Angers","zip":"49033","country":"France","geoPoint":{"lat":47.47156,"lon":-0.55202}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Annecy","zip":"74011","country":"France","geoPoint":{"lat":45.90878,"lon":6.12565}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bron","zip":"69500","country":"France","geoPoint":{"lat":45.73865,"lon":4.91303}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dijon","zip":"21079","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Narbonne","zip":"11108","country":"France","geoPoint":{"lat":43.18396,"lon":3.00141}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nevers","zip":"58000","country":"France","geoPoint":{"lat":46.98956,"lon":3.159}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nice","zip":"06002","country":"France","geoPoint":{"lat":43.70313,"lon":7.26608}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chemitz","zip":"09111","country":"Germany"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dresden","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mainz","zip":"D-55116","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Münster","zip":"48145","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Schkeuditz","zip":"04435","country":"Germany","geoPoint":{"lat":51.39678,"lon":12.22141}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Siegen","zip":"57072","country":"Germany","geoPoint":{"lat":50.87481,"lon":8.02431}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Würzburg","zip":"97070","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Genova","zip":"16132","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Perugia","zip":"06100","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rome","zip":"00161","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}}]},"referencesModule":{"references":[{"pmid":"19637208","type":"RESULT","citation":"Skljarevski V, Desaiah D, Zhang Q, Chappell AS, Detke MJ, Gross JL, Ziegler D. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev. 2009 Oct;25(7):623-31. doi: 10.1002/dmrr.1000."},{"pmid":"20465525","type":"DERIVED","citation":"Hall JA, Wang F, Oakes TM, Utterback BG, Crucitti A, Acharya N. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Expert Opin Drug Saf. 2010 Jul;9(4):525-37. doi: 10.1517/14740338.2010.484418."}],"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Study Period I was a 5-9 day Screening Phase. Study Period II was an 8 week Acute Therapy Phase. Study Period III was a 26 week Maintenance and Rescue Therapy Phase. Study Period IV was a 2 week Taper Phase.","groups":[{"id":"FG000","title":"Acute Phase","description":"All subjects receive 30 milligrams (mg) duloxetine once daily (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months."},{"id":"FG001","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily."},{"id":"FG002","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily."}],"periods":[{"title":"Period II - Acute Therapy Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"216"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"184"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Period III - Maintenance / Rescue Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"115"},{"groupId":"FG002","numSubjects":"69"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"86"},{"groupId":"FG002","numSubjects":"33"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"36"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"5"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"24"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"5"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Acute Phase","description":"All subjects receive 30 milligrams (mg) duloxetine once daily (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"216"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.3","spread":"9.45"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"104"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"112"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"43"}]}]},{"title":"Brazil","categories":[{"measurements":[{"groupId":"BG000","value":"66"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"66"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"41"}]}]}]},{"title":"Duration of Diabetes","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"<=2 years","categories":[{"measurements":[{"groupId":"BG000","value":"78"}]}]},{"title":">2 years","categories":[{"measurements":[{"groupId":"BG000","value":"138"}]}]}]},{"title":"Duration of Neuropathic Pain","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"<=1 year","categories":[{"measurements":[{"groupId":"BG000","value":"38"}]}]},{"title":">1 year","categories":[{"measurements":[{"groupId":"BG000","value":"178"}]}]}]},{"title":"Race/Ethnicity","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"173"}]}]},{"title":"West Asian","categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}]},{"title":"African","categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]}]},{"title":"Type of Diabetes Mellitus","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Type 1","categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}]},{"title":"Type 2","categories":[{"measurements":[{"groupId":"BG000","value":"204"}]}]}]},{"title":"Brief Pain Inventory 24-Hour Average Pain Severity","description":"A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5.88","spread":"1.45"}]}]}]},{"title":"Height at Visit 1 (Week -1)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"centimeters (cm)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"166.7","spread":"10.39"}]}]}]},{"title":"Weight at Visit 2 (Week 0)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"84.0","spread":"18.36"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (Week 8) in Brief Pain Inventory (BPI) 24-hour Average Pain Item Score at Week 34 Endpoint","description":"Maintenance effect of duloxetine 60 mg in patients with diabetic peripheral neuropathic pain (DPNP) was assessed by the change in BPI 24-hour average pain item score from baseline of the maintenance therapy arm (week 8) to 34 week endpoint in patients who achieved at least a 30 percent reduction on the BPI 24-hour average pain item after 8 weeks of acute therapy (Acute Therapy Phase). BPI is a self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Patients entering maintenance phase on duloxetine 60 mg QD. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"2.09"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Null hypothesis is that duloxetine treatment effect on pain reduction in diabetic peripheral neuropathic pain (DPNP) is not maintained, as indicated by an increase of more than 1.5 point on the BPI 24-hour average pain scale. Null hypothesis is rejected at significance level 0.025 if the upper bound of one-sided 97.5% CI is less than or equal to non-inferiority margin of 1.5 point.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"Non-inferiority margin of 1.5 point on the BPI 24-hour average pain scale.","pValue":"<0.001","pValueComment":"Significance level 0.025","statisticalMethod":"t-test, 1 sided","paramType":"Mean Difference (Net)","paramValue":"0.35","ciPctValue":"97.5","ciLowerLimit":"0.35","ciUpperLimit":"0.79"}]},{"type":"SECONDARY","title":"Maintenance Arm: Number of Patients With a ≥50% Reduction From Baseline (Week 0) in Brief Pain Inventory 24-hour Average Pain Item","description":"A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline (Week 0), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76"}]}]}]},{"type":"SECONDARY","title":"Rescue Arm: Number of Patients With a ≥50% Reduction From Baseline (Week 0) in Brief Pain Inventory 24-hour Average Pain Item","description":"A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline (Week 0), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Worst Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the worst pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"2.78"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.269","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Worst Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the worst pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.33","spread":"2.96"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Least Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the least pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"1.79"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.160","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Least Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the least pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"3.07"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.016","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Pain Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"2.09"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.075","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Pain Score at 34 Week Endpoint","description":"A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"2.57"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Pain Right Now Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the pain right now. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"2.28"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.026","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Pain Right Now Score at Week 34 Endpoint","description":"A self-reported scale that measures the severity of pain based on the pain right now. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"3.49"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.011","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: General Activity at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on general activity. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"2.73"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.406","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: General Activity at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on general activity. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":"3.53"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.021","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Mood at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on mood. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"2.63"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.124","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Mood at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on mood. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"3.62"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.505","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Walking Ability at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on walking ability. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"3.22"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.058","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Walking Ability at 34 Week Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on walking ability. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"3.49"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.009","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Normal Work at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on normal work. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"2.72"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.016","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Normal Work at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on normal work. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"3.40"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.022","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Relations With Other People at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on relations with other people. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"2.22"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.550","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Relations With Other People at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on relations with other people. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"3.08"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.752","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Sleep at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on sleep. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"2.83"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.713","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Sleep at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on sleep. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"3.69"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.066","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Enjoyment of Life at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on enjoyment of life. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"3.06"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.711","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Interference Score: Enjoyment of Life at Week 34 Endpoint","description":"A self-reported scale that measures the interference of pain in the past 24 hours on enjoyment of life. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"3.79"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.678","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Interference at Week 34 Endpoint","description":"A self-reported scale that measures interference of pain on average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"2.34"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.216","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Brief Pain Inventory Average Interference at Week 34 Endpoint","description":"A self-reported scale that measures interference of pain on average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average Interference scores range from 0 (does not interfere) to 10 (completely interferes).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.59","spread":"3.04"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.113","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Patient's Global Impressions of Improvement (PGI-I) at Week 34 Endpoint","description":"A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).","populationDescription":"Number of responders with at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.32","spread":"1.33"}]}]}]},{"type":"SECONDARY","title":"Rescue Arm: Patient's Global Impressions of Improvement (PGI-I) at Week 34 Endpoint","description":"A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.04","spread":"1.32"}]}]}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Clinical Global Impressions of Severity (CGI-S) at Week 34 Endpoint","description":"Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"1.24"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.368","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Clinical Global Impressions of Severity (CGI-S) at Week 34 Endpoint","description":"Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"1.23"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Sensory Portion of the Short-Form McGill Pain Questionnaire at Week 34 Endpoint","description":"This instrument consists of 11 pain descriptors. The sensory pain portion scores range from 0 (none) to 3 (severe).","populationDescription":"Number of responders with a baseline and ate least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"7.34"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.666","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Sensory Portion of the Short-Form McGill Pain Questionnaire at Week 34 Endpoint","description":"This instrument consists of 11 pain descriptors. The sensory pain portion scores range from 0 (none) to 3 (severe).","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.38","spread":"7.60"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.138","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Maintenance Arm: Change From Baseline (Week 8) in Beck Depression Inventory-II (BDI-II) Total Score at Week 34 Endpoint","description":"A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.","populationDescription":"Number of responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Maintenance Arm","description":"Duloxetine: 60 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"5.80"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.145","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rescue Arm: Change From Baseline (Week 8) in Beck Depression Inventory-II (BDI-II) Total Score at Week 34 Endpoint","description":"A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.","populationDescription":"Number of non-responders with a baseline and at least one non-missing post-baseline score. Endpoint is the last non-missing measure from Week 12 to Week 34. Last observation carried forward.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (Week 8), Week 34","groups":[{"id":"OG000","title":"Rescue Arm","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"6.62"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.512","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Number of Participants Discontinuing in the Acute Phase","populationDescription":"Participants in Acute Phase (through Week 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline (Week 0) to Week 8","groups":[{"id":"OG000","title":"Acute Phase","description":"All subjects receive 30 milligrams (mg) duloxetine once daily (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"216"}]}],"classes":[{"title":"Initiating at Week 0","categories":[{"measurements":[{"groupId":"OG000","value":"216"}]}]},{"title":"Continuing at Week 1","categories":[{"measurements":[{"groupId":"OG000","value":"201"}]}]},{"title":"Continuing at Week 8","categories":[{"measurements":[{"groupId":"OG000","value":"184"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Discontinuing in Maintenance / Rescue Phase","populationDescription":"Participants in Maintenance / Rescue Phase (beyond Week 8 through Week 34)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline (Week 8) to Week 34","groups":[{"id":"OG000","title":"All Maintenance / Rescue Participants","description":"Total of the Maintenance (No Dose Increase), Maintenance (Later Dose Increase) and Rescue arms. Depending on the group the patient was in, they either received duloxetine 60 mg once daily; 60 mg once daily and then increased to 120 mg once daily; or 120 mg once daily."},{"id":"OG001","title":"Maintenance Arm (No Dose Increase)","description":"duloxetine 60 mg once daily"},{"id":"OG002","title":"Maintenance Arm (Later Dose Increase)","description":"duloxetine 60 mg once daily and then increasing to 120 mg once daily"},{"id":"OG003","title":"Rescue Arm","description":"duloxetine 120 mg once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"103"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"69"}]}],"classes":[{"title":"Entering at Week 8","categories":[{"measurements":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"103"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"69"}]}]},{"title":"Continuing at Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"63"}]}]},{"title":"Continuing at Week 16","categories":[{"measurements":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"39"}]}]},{"title":"Continuing at Week 24","categories":[{"measurements":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"84"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"34"}]}]},{"title":"Completing at Week 34","categories":[{"measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Vital Signs: Heart Rate at Week 34 Endpoint","populationDescription":"All patients who received either 60 mg or 120 mg duloxetine once daily.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats per minute","timeFrame":"Baseline (Week 0), Week 34","groups":[{"id":"OG000","title":"Duloxetine 60 mg","description":"Duloxetine: 60 milligrams once daily"},{"id":"OG001","title":"Duloxetine 120 mg","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"10.78"},{"groupId":"OG001","value":"0.4","spread":"11.46"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) in Vital Signs: Diastolic Blood Pressure at Week 34 Endpoint","populationDescription":"All patients who received either 60 mg or 120 mg duloxetine once daily.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mm Hg","timeFrame":"Baseline (Week 0), Week 34","groups":[{"id":"OG000","title":"Duloxetine 60 mg","description":"Duloxetine: 60 milligrams once daily"},{"id":"OG001","title":"Duloxetine 120 mg","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"9.39"},{"groupId":"OG001","value":"-1.0","spread":"9.18"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) in Vital Signs: Systolic Blood Pressure at Week 34 Endpoint","populationDescription":"All patients who received either 60 mg or 120 mg duloxetine once daily.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mm Hg","timeFrame":"Baseline (Week 0), Week 34","groups":[{"id":"OG000","title":"Duloxetine 60 mg","description":"Duloxetine: 60 milligrams once daily"},{"id":"OG001","title":"Duloxetine 120 mg","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"14.94"},{"groupId":"OG001","value":"0.7","spread":"15.27"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) in Vital Signs: Weight at Week 34 Endpoint","populationDescription":"All patients who received either 60 mg or 120 mg duloxetine once daily.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilograms (kg)","timeFrame":"Baseline (Week 0), Week 34","groups":[{"id":"OG000","title":"Duloxetine 60 mg","description":"Duloxetine: 60 milligrams once daily"},{"id":"OG001","title":"Duloxetine 120 mg","description":"Duloxetine: 120 milligrams once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"4.17"},{"groupId":"OG001","value":"0.2","spread":"3.16"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"34 Weeks","description":"There were 12 patients who began the maintenance dose group who had their dose increased to rescue dose of 120 mg QD at some point during the maintenance period. Adverse events reported were attributed to the dose the participant was on at the time of the event, therefore, the 12 participants were also included in the 120 mg QD group.","eventGroups":[{"id":"EG000","title":"Duloxetine 60 mg","description":"Duloxetine: 60 milligrams once daily","seriousNumAffected":18,"seriousNumAtRisk":216,"otherNumAffected":135,"otherNumAtRisk":216},{"id":"EG001","title":"Duloxetine 120 mg","description":"Duloxetine: 120 milligrams once daily","seriousNumAffected":2,"seriousNumAtRisk":81,"otherNumAffected":40,"otherNumAtRisk":81}],"seriousEvents":[{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Oesophageal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Viral labyrinthitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81}]},{"term":"Anuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Diabetic neuropathic ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]}],"otherEvents":[{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":216},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":81}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":216},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":81}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":216},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":216},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":81}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":216},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":41,"numAtRisk":216},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":81}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":216},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":81}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":216},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":11,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":216},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81}]},{"term":"Excoriation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":216},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":81}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Diabetic foot","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":81}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":216},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":81}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":6,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":216},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":81}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":216},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":11,"numAtRisk":216},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":81}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":216},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":81}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":216},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":81}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":216},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":216},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":216},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":81}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":216},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":81}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"1-800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003929","term":"Diabetic Neuropathies"}],"ancestors":[{"id":"D010523","term":"Peripheral Nervous System Diseases"},{"id":"D009468","term":"Neuromuscular Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D048909","term":"Diabetes Complications"},{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068736","term":"Duloxetine Hydrochloride"}],"ancestors":[{"id":"D013876","term":"Thiophenes"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}